Global market potential MiStent SES is CE-marked and already distributed in multiple countries through a partner network, indicating established international demand and a scalable go-to-market approach suitable for expansion into additional regions.

Targeted cardiovascular focus The company’s supercritical fluid technology enhances drug-eluting devices for interventional cardiology with potential applications across cardiovascular disease, presenting cross-sell and upsell opportunities within cardiology product lines and adjacent markets.

Strategic acquisition Acquisition by Kossel Medical in late 2021 and ongoing global strategy execution suggest a stronger platform for accelerated international sales, channel optimization, and potential co-development with larger medical device ecosystems.

Invested funding runway Significant funding with a reported $90M plus a prior $6M financing round indicates ample capital for sales expansion, clinical studies, and regulatory activities to broaden adoption and support in new markets.

Sales expansion gaps Limited U S. sales authorization for MiStent SES highlights a qualification and regulatory opportunity; prospect to address reimbursement, FDA pathway strategies, and hospital adoption to unlock U.S. revenue potential.